Top Story Today
The SMA Drug That Treats Muscles by Ignoring the Broken Gene
Every SMA treatment on the market fixes the same broken gene. The FDA just approved one that skips the gene entirely and goes straight to the muscle. Scholar Rock's Isembyld (apitegromab) is the first muscle-targeted SMA therapy, designed to be layered on top of existing treatments rather than replace them. It works by blocking myostatin, a protein that caps muscle growth, essentially removing the speed limiter on muscles that are wasting away. In clinical trials, 30% of patients on the drug gained meaningful motor function versus 12.5% on placebo. The kicker: this approach succeeded after decades of myostatin inhibitor failures in other diseases.
Why it matters: This first-in-class approval creates an entirely new treatment layer for SMA, proving that targeting downstream muscle biology (not just the genetic defect) can deliver real functional gains, a concept the industry had nearly abandoned after years of expensive failures.
Read more →Gene Therapy and Oncology Setbacks
Two Children Died. Now Sarepta Is Fighting to Survive.
Two boys died of liver failure after receiving Sarepta's Duchenne gene therapy Elevidys, triggering a black box warning, a restricted label, and 500 layoffs (36% of the company). The crisis extends beyond one drug: the FDA broadened its investigation to other Sarepta AAV therapies after a third death surfaced. The stock has cratered to roughly $22, and the entire AAV gene therapy field is facing a safety reckoning.
Read more →AstraZeneca's Cancer Pill Got Approved, Then Failed Its Biggest Trial Eight Days Later
Camizestrant won FDA approval on September 4 for ESR1-mutant breast cancer. By September 12, it had failed the primary endpoint in SERENA-4, the trial meant to prove it could be a first-line treatment for all ER-positive patients. The drug keeps its niche, but the blockbuster dream just got significantly harder in a crowded oral SERD race.
Read more →Exelixis' Colorectal Cancer Combo Gets a Three-Month FDA Delay
The FDA pushed its decision on Exelixis' zanzalintinib plus atezolizumab combo from December 2026 to March 2027 after classifying updated data as a major amendment. The trial showed a significant overall survival benefit, but a key subgroup result didn't reach statistical significance, likely prompting the closer look.
Read more →Breakthroughs and Big Bets
The First Personalized Cancer Vaccine Just Passed Its Final Exam
Moderna and Merck's intismeran, a custom mRNA vaccine built from each patient's unique tumor mutations, hit both primary and key secondary endpoints in a 1,137-patient Phase 3 melanoma trial. It's the first personalized neoantigen therapy to succeed at this stage. The catch: every dose must be manufactured from scratch for a single patient, a logistical puzzle the industry has never solved at scale.
Read more →A Brand-New Biotech Just Debuted With $225 Million and a Plan for Cold Tumors
Solstice Oncology emerged from stealth with one of the largest Series A rounds in recent memory, targeting MSS colorectal cancer, a tumor type that has humbled nearly every immunotherapy attempt. Its lead drug porustobart is a next-gen CTLA-4 antibody that removes the brakes on the immune system while depleting the regulatory T cells that keep cold tumors cold.
Read more →Regulatory and Legal
J&J Just Locked Generic Spravato Out Until 2035
A federal court blocked Sandoz from launching generic Spravato, J&J's blockbuster depression nasal spray, until September 2035. The drug hit $1.08 billion in 2024 sales and is projected to reach $5 billion at peak. For generics companies, layered patent portfolios and REMS distribution requirements make this fortress nearly impossible to breach.
Read more →The FDA Commissioner Reportedly Tried to Block a Rare Disease Drug. Scientists Said No.
FDA Commissioner Marty Makary allegedly pushed staff to reject KalVista's hereditary angioedema drug sebetralstat, but senior scientists warned the move could be deemed arbitrary and capricious. The request was withdrawn and the drug was approved. HHS denies the story entirely, but the episode raises uncomfortable questions about political interference in scientific review.
Read more →The FDA's New Oncology Chief Wants to Hire More Reviewers and Deploy AI
Angelo de Claro, who took the permanent role in May 2026, laid out a plan to address the oncology division's staffing crisis while deploying AI tools to help reviewers process massive drug submissions faster. The approach treats AI as GPS for reviewers, not a replacement.
Read more →